tradingkey.logo

ARS Pharmaceuticals Inc

SPRY
View Detailed Chart

17.450USD

-0.750-4.12%
Close 06/30, 16:00ETQuotes delayed by 15 min
1.71BMarket Cap
214.10P/E TTM

ARS Pharmaceuticals Inc

17.450

-0.750-4.12%
Intraday
1m
30m
1h
D
W
M
D

Today

-4.12%

5 Days

+5.31%

1 Month

+20.93%

6 Months

+65.40%

Year to Date

+65.40%

1 Year

+105.05%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 6 analysts
STRONG BUY
Current Rating
32.000
Target Price
83.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

556
Total
5
Median
6
Average
Company name
Ratings
Analysts
ARS Pharmaceuticals Inc
SPRY
6
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Regeneron Pharmaceuticals Inc
REGN
28
Exact Sciences Corp
EXAS
27
Moderna Inc
MRNA
26
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(1)
Neutral(0)
Buy(9)
Indicators
Sell(1)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MACD(12,26,9)
0.661
Buy
RSI(14)
73.882
Buy
STOCH(KDJ)(9,3,3)
87.729
Overbought
ATR(14)
0.801
High Vlolatility
CCI(14)
159.422
Buy
Williams %R
14.583
Overbought
TRIX(12,20)
0.761
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
17.378
Buy
MA10
16.397
Buy
MA20
15.355
Buy
MA50
14.603
Buy
MA100
13.344
Buy
MA200
13.498
Buy

News

More news coming soon, stay tuned...

Company

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Ticker SymbolSPRY
CompanyARS Pharmaceuticals Inc
CEOMr. Richard E. Lowenthal
Websitehttps://ars-pharma.com/
KeyAI